Navigation Links
Scientists identify prostate cancer stem cells among low-PSA cells
Date:5/4/2012

androgen receptor, allowing them to grow while hormonal therapy wipes out PSA-positive cells; and
  • Can divide into one copy of themselves and one PSA-positive cell during reproduction. The researchers captured this on video microscopy, filming the division of a grey low-PSA cell into one copy of itself and one copy of a vibrantly green PSA-positive cell.

    Low-PSA tumors have long-term tumor-generating capacity

    When the team implanted the two cell types in hormonally intact male mice, the rapidly reproducing PSA-positive cells caused faster growth and larger tumors in the first generation. However, after that the low-PSA cells generated larger, faster-growing tumors and tumor incidence in the high-PSA cells dropped. In fact, the low-PSA prostate cancer cells possess indefinite tumor-propagating capacity.

    In contrast, when implanted in the castrated mice, the low-PSA prostate cancer cells developed much larger tumors than the corresponding high-PSA cells. In another experiment, mice with tumors generated by either cell type were then castrated and treated with hormonal therapy. Low-PSA tumors grew better in these doubly androgen-deprived mice than the high-PSA tumors.

    "These findings closely resemble progression observed in patients after androgen-deprivation treatment and reflect reducedPSA-producing cells in patient tumors after androgen depletion," Tang said.

    Effect of low-PSA cells in human tumors

    Tang and colleagues analyzed tumor cell PSA expression in 556 human tumors and found low protein levels correlated with reduced overall survival.

    They separated the two types of cells in three primary human tumors and found that low-PSA cells did not express androgen receptor and have higher cell-generating and sphere-forming capabilities than high-PSA cells.

    Future research will focus on developing therapeutic targets for low-PSA cells and illuminating the epigenetic landscapes of b
    '/>"/>


  • Contact: Scott Merville
    smerville@mdanderson.org
    713-792-0655
    University of Texas M. D. Anderson Cancer Center
    Source:Eurekalert

    Page: 1 2 3 4

    Related biology news :

    1. Scientists core into Californias Clear Lake to explore past climate change
    2. Scientists make stunning inner space observations
    3. Scientists discover enzyme that could slow part of the aging process in astronauts -- and the elderly
    4. Scientists uncover exciting lead into premature aging and heart disease
    5. March of Dimes awards $250,000 prize to 2 scientists who pioneered advances in skin disorders
    6. Scientists provide first large-scale estimate of reef shark losses in the Pacific Ocean
    7. Stanford and MIT scientists win Perl-UNC Neuroscience prize
    8. Queens is UK leader for female scientists and engineers
    9. Scientists uncover strong support for once-marginalized theory on Parkinsons disease
    10. Scientists develop new technique that could improve heart attack prediction
    11. Scientists advance field of research with publication of newly validated method for analyzing flavanols in cocoa
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/3/2015)... , Aug. 3, 2015 Synaptics, Inc. ... interface solutions, today announced that members of the executive ... the Pacific Crest Global Technology Leadership Forum on Tuesday, ... conference will be held at the Sonnenalp Resort in ... The presentation may include forward-looking information. An audio webcast ...
    (Date:7/31/2015)... Kina, 31. juli 2015 Den 10. internationale ... af BGI fra den 22. - 25. oktober i ... fejrer sin 10-års fødselsdag i år. Siden starten i ... årlige møder på ,omik,-feltet, og er en af de ... ICG-10 fokuserer på nylige gennembrud og fremskridt inden ...
    (Date:7/31/2015)... de 2015 BGI llevará a cabo la 10ª ... al 25 de octubre de 2015, en ... su décimo aniversario este año. Desde su inauguración en ... reuniones anuales más influyentes del mundo en los campos ... científicas más dinámicas, entusiastas y amenas. ICG-10 ...
    Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
    ... -- (July 29, 2009) -- Italian and U.S. biologists this ... rare genetic disorder plays an unexpected and critical role in ... in the journal Nature shows that the protein, ... a previously undocumented way. "If you,d asked me a ...
    ... obesity have tripled in the last 25 years, putting many ... a report in Academic Pediatrics by an obesity ... Baptist Medical Center. "Children are not only becoming ... said Joseph Skelton, M.D., lead author and director of the ...
    ... is a longtime user of the Advanced Light Source ... to major advances in lensless imaging. It,s a particularly ... they can,t be focused with ordinary lenses. ... in faster pulses, lensless imaging becomes ever more critical ...
    Cached Biology News:Little-known protein found to be key player 2Research shows rates of severe childhood obesity have tripled 2Jet-propelled imaging for an ultrafast light source 2Jet-propelled imaging for an ultrafast light source 3Jet-propelled imaging for an ultrafast light source 4Jet-propelled imaging for an ultrafast light source 5Jet-propelled imaging for an ultrafast light source 6
    (Date:7/30/2015)... ... July 30, 2015 , ... Leading regenerative ... study of its canine osteoarthritis stem cell product, currently under development for FDA ... and will be marketed in the US by Aratana. This product, termed AT-016, ...
    (Date:7/30/2015)... , July 30, 2015 Ascendis ... company that applies its innovative TransCon technology to ... top-line results from a six-month Phase 2 study ... TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal children ... "We are extremely pleased with the top-line results ...
    (Date:7/30/2015)... ... 2015 , ... GEA's Pony™ NS2006L is a ... to 1500 bar. The sanitary design gauge of the NS2006L is well suited ... Pony™ NS2006L homogenizer is an ideal solution for the processing of nanoparticles, ...
    (Date:7/29/2015)... SYDNEY , July 29, 2015 US-Australian ... NVGN ) today confirmed it is committed to progressing ... as soon as practicable and to ensure the Company ... Chief Executive Officer, Iain Ross , said the ... including the lead pre-clinical programs, discovery programs and academic ...
    Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
    ... August 15 XTL,Biopharmaceuticals Ltd. (NASDAQ: XTLB ... in the acquisition, development and,commercialization of therapeutics for ... and hepatitis C, today announced its,financial results for ... At June 30, 2007, the Company had cash, ...
    ... Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), ... period under,Hart-Scott-Rodino Antitrust Improvements Act of 1976 with ... BETA 3) from Renovo Group plc,(LSE: RNVO) expired ... terms, the,License Agreement became effective on August 15, ...
    ... Amyris Co-founder Recognized for Role in Engineering Microbes to Produce ... TR35 2007 Recipients to be Honored at Technology Review,s ... ... Amyris Biotechnologies is,pleased to announce that Neil Renninger, Ph.D., ...
    Cached Biology Technology:XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 2XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 3XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 4XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 5XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 6XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 7XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 8XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 9XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 10XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 11XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 12XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 13XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 14Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3) 2Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3) 3Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Review's Prestigious TR35 List of Top Young Innovators 2Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Review's Prestigious TR35 List of Top Young Innovators 3
    ... Application: For the efficient enrichment of ... tissue or cell culture. The isolated ... degradation and metabolic pathway analysis. Metabolic ... deficiency in children, cystic fibrosis and ...
    Plasmid expressing the LacZ reporter gene....
    ... PYREX Fernbach-style culture flasks have triple baffles ... bottom to achieve maximal oxygen transfer to ... marking spot., A wide range of optional ... Polypropylene colored caps for ease of ...
    ...
    Biology Products: